Jacobs Levy Equity Management, Inc Syndax Pharmaceuticals Inc Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$13.64 - $19.48 $377,336 - $538,894	-27,664 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$14.84 - $22.15 $410,533 - $612,757	27,664 New	27,664 $481,000
Q2 2020 Aug 17, 2020	SELL	$8.94 - $20.98 $726,357 - $1.7 Million	-81,248 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$6.65 - $12.03 $137,681 - $249,069	-20,704 Reduced 20.31%	81,248 $891,000
Q4 2019 Feb 14, 2020	BUY	$5.43 - $9.22 $120,589 - $204,757	22,208 Added 27.85%	101,952 $895,000
Q3 2019 Nov 14, 2019	BUY	$7.47 - $10.76 $356,408 - $513,381	47,712 Added 148.95%	79,744 $596,000
Q2 2019 Aug 13, 2019	BUY	$4.9 - $9.31 $77,576 - $147,395	15,832 Added 97.73%	32,032 $298,000
Q1 2019 May 14, 2019	SELL	$4.26 - $6.86 $113,908 - $183,429	-26,739 Reduced 62.27%	16,200 $85,000
Q4 2018 Feb 14, 2019	SELL	$3.6 - $8.42 $75,513 - $176,617	-20,976 Reduced 32.82%	42,939 $191,000
Q3 2018 Nov 14, 2018	BUY	$6.33 - $8.08 $146,223 - $186,648	23,100 Added 56.6%	63,915 $516,000
Q2 2018 Aug 14, 2018	BUY	$6.93 - $14.63 $282,847 - $597,123	40,815 New	40,815 $287,000

227

88.3M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $895M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.